164 related articles for article (PubMed ID: 37228591)
21. Transient optic neuropathy secondary to MOPP chemotherapy in Hodgkin's disease: report of a case.
Vecchi V; Maccolini E; Oddo Bravetti G; Guidelli Guidi S; Serra L
Tumori; 1984 Dec; 70(6):571-3. PubMed ID: 6549418
[TBL] [Abstract][Full Text] [Related]
22. Optic Neuritis Possibly Induced by Anti-PD-L1 Antibody Treatment in a Patient with Non-Small Cell Lung Carcinoma.
Mori S; Kurimoto T; Ueda K; Enomoto H; Sakamoto M; Keshi Y; Yamada Y; Nakamura M
Case Rep Ophthalmol; 2018; 9(2):348-356. PubMed ID: 30140221
[TBL] [Abstract][Full Text] [Related]
23. Ethambutol/Linezolid Toxic Optic Neuropathy.
Libershteyn Y
Optom Vis Sci; 2016 Feb; 93(2):211-7. PubMed ID: 26636399
[TBL] [Abstract][Full Text] [Related]
24. Retrobulbar Optic Neuritis Induced by Pembrolizumab in a Patient with Lung Adenocarcinoma.
Kawakado K; Tamura T; Nakanishi M; Makimoto G; Kuyama S
Intern Med; 2021 Dec; 60(24):3941-3945. PubMed ID: 34148963
[TBL] [Abstract][Full Text] [Related]
25. [Methotrexate in Atypical Non-Arteritic Ischemic Optic Neuropathy].
Lenk J; Hermann C; Matthé E; Pillunat LE; Sandner D
Klin Monbl Augenheilkd; 2017 Jul; 234(7):924-929. PubMed ID: 27508886
[No Abstract] [Full Text] [Related]
26. Case Report: Linezolid Optic Neuropathy and Proposed Evidenced-based Screening Recommendation.
Dempsey SP; Sickman A; Slagle WS
Optom Vis Sci; 2018 May; 95(5):468-474. PubMed ID: 29683987
[TBL] [Abstract][Full Text] [Related]
27. Optic neuropathy associated with botulinum A toxin in thyroid-related orbitopathy.
Korn BS; Seo SW; Levi L; Granet DB; Kikkawa DO
Ophthalmic Plast Reconstr Surg; 2007; 23(2):109-14. PubMed ID: 17413623
[TBL] [Abstract][Full Text] [Related]
28. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
Merryman RW; Redd R; Jeter E; Wong JL; McHugh K; Reynolds C; Nazzaro M; Varden A; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Dahi PB; Nieto Y; Joyce RM; Chen YB; Herrera AF; Armand P; Ritz J
Transplant Cell Ther; 2022 Jan; 28(1):32.e1-32.e10. PubMed ID: 34670169
[TBL] [Abstract][Full Text] [Related]
29. A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma.
Matsui H; Kawai T; Sato Y; Ishida J; Kadowaki H; Akiyama Y; Yamada Y; Nakamura M; Yamada D; Akazawa H; Suzuki M; Komuro I; Kume H
Int Heart J; 2020 Sep; 61(5):1070-1074. PubMed ID: 32921673
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
[TBL] [Abstract][Full Text] [Related]
31. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Zhang M; Rodrigues AJ; Pollom EL; Gibbs IC; Soltys SG; Hancock SL; Neal JW; Padda SK; Ramchandran KJ; Wakelee HA; Chang SD; Lim M; Hayden Gephart M; Li G
J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659
[TBL] [Abstract][Full Text] [Related]
32. Anterior optic neuropathy associated with adalimumab.
von Jagow B; Kohnen T
Ophthalmologica; 2008; 222(4):292-4. PubMed ID: 18560250
[TBL] [Abstract][Full Text] [Related]
33. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
35. Pembrolizumab-Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors.
Feng S; Coward J; McCaffrey E; Coucher J; Kalokerinos P; O'Byrne K
J Thorac Oncol; 2017 Nov; 12(11):1626-1635. PubMed ID: 28843363
[TBL] [Abstract][Full Text] [Related]
36. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
[TBL] [Abstract][Full Text] [Related]
37. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
[TBL] [Abstract][Full Text] [Related]
38. Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin's lymphoma progressing after brentuximab vedotin: an indirect treatment comparison.
Keeping S; Wu E; Chan K; Mojebi A; Ferrante SA; Balakumaran A
Expert Rev Hematol; 2018 Jun; 11(6):503-511. PubMed ID: 29764245
[TBL] [Abstract][Full Text] [Related]
39. [Successful treatment of Guillain-Barré syndrome-like acute inflammatory demyelinating polyneuropathy caused by pembrolizumab with a combination of corticosteroid and immunoglobulins: a case report].
Hashimoto R; Ueda T; Tsuji Y; Otsuka Y; Sekiguchi K; Matsumoto R
Rinsho Shinkeigaku; 2020 Nov; 60(11):773-777. PubMed ID: 33115993
[TBL] [Abstract][Full Text] [Related]
40. An evaluation of pembrolizumab for classical Hodgkin lymphoma.
Manji F; Laister RC; Kuruvilla J
Expert Rev Hematol; 2022 Apr; 15(4):285-293. PubMed ID: 35389317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
